https://www.globenewswire.com/news-release/2023/02/13/2607171/0/en/MacroGenics-Announces-Preliminary-Clinical-Results-from-Single-Arm-Study-of-Lorigerlimab-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer-to-be-Presented-at-ASCO-Ge.html
0
0
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium - GlobeNewswire
+ 135 more
2/13/23 at 10:20pm
Organization
GlobeNewswire
Authors
MacroGenics Inc.
Details
48 words
Summarize
Cancer Health MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab ASCO Genitourinary Cancers Symposium - GlobeNewswire Twelve Prostate Cancer
Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA)...
Create an account or login to join the discussion